Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous BAY 1179470 in Subjects With Advanced, Refractory Solid Tumors.

NCT01881217 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01881217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01881217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous BAY 1179470 in Subjects With Advanced, Refractory Solid Tumors.
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
June 28, 2013
Completion date
August 16, 2016
Enrollment
35 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms